A Perspective of Immunotherapy for Prostate Cancer

PMID: 27399780
Journal: Cancers (volume: 8, issue: 7, Cancers (Basel) 2016 Jul;8(7))
Published: 2016-07-07

Authors:
Silvestri I, Cattarino S, Giantulli S, Nazzari C, Collalti G, Sciarra A

ABSTRACT

In cancer patients, the immune system is often altered with an excess of inhibitory factors, such as immunosuppressive cytokines, produced by regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC). The manipulation of the immune system has emerged as one of new promising therapies for cancer treatment, and also represents an attractive strategy to control prostate cancer (PCa). Therapeutic cancer vaccines and immune checkpoint inhibitors have been the most investigated in clinical trials. Many trials are ongoing to define the effects of immune therapy with established treatments: androgen deprivation therapy (ADT) and chemotherapy (CT) or radiotherapy (RT). This article discusses some of these approaches in the context of future treatments for PCa.